Core Points - The stock price of You Ning Wei (301166) closed at 29.86 yuan on June 13, 2025, with no change from the previous week, and reached a high of 30.65 yuan on June 10, 2025 [1] - The total market capitalization of You Ning Wei is 2.588 billion yuan, ranking 48th out of 50 in the biopharmaceutical sector and 4527th out of 5150 in the A-share market [1] - A block trade occurred on June 9, 2025, with a transaction amount of 6.576 million yuan [1] - Shareholders Shanghai Chuangye Jieli Tai Li Venture Capital Center and Shanghai Tai Li Venture Capital Management reduced their holdings by 462,400 shares, representing 0.5336% of the total share capital, during a period when the stock price increased by 1.14% [1] Company Announcements - You Ning Wei announced the cancellation of a special account for raised funds, with a total of 21,666,668 shares issued at a price of 8,606 yuan per share, raising a total of 18.646 billion yuan [2] - After deducting issuance costs of 269.1162 million yuan, the net amount raised was 15.955173 billion yuan, with all funds received and verified by Tianzhi International Accounting Firm [2] - The company has closed some special accounts for raised funds, including the cancellation of an account at Bank of China, with surplus funds of 396,227 yuan transferred to the general account for daily operational liquidity [2]

Core Viewpoint - The A-share pharmaceutical sector, particularly the innovative drug segment, has shown strong performance, with R&D investment becoming a critical variable for company success in a competitive environment [1] Group 1: R&D Investment Overview - The total R&D expenditure of A-share pharmaceutical companies has steadily increased over the past three years, reaching 111.11 billion yuan in 2022, 118.50 billion yuan in 2023, and projected to be 121.01 billion yuan in 2024 [2][3] - The chemical pharmaceutical sector leads in R&D spending, with an expected 2024 expenditure close to 60 billion yuan, followed by the medical device sector at over 23 billion yuan and the biological products sector at 16.87 billion yuan [2][3] Group 2: R&D Intensity - The R&D intensity, measured as the ratio of R&D expenditure to revenue, ranks the biological products sector highest at 13.01%, followed by chemical pharmaceuticals at 10.87% and medical devices at 9.68% for 2024 [4][5] Group 3: Performance of Key Sectors - Despite overall pressure on performance, the chemical pharmaceutical sector has shown consistent growth, with net profits increasing from 21.68 billion yuan in 2022 to 34.44 billion yuan in 2024 [3][14] - The medical device sector has faced significant declines, with net profits dropping from 80.28 billion yuan in 2022 to 33.18 billion yuan in 2024, a nearly 59% decrease [3][14] Group 4: Leading Companies in R&D Investment - Among biological products companies, Changchun High-tech leads with an average R&D investment of 2.26 billion yuan over the past three years, showing a growth of over 60% from 1.66 billion yuan in 2022 to 2.69 billion yuan in 2024 [10][11] - In the chemical pharmaceutical sector, BeiGene has the highest average R&D investment at 12.70 billion yuan, with a significant reduction in losses from 13.64 billion yuan in 2022 to 4.98 billion yuan in 2024 [12][14] - In the medical device sector, Mindray Medical tops the list with an average R&D investment of 3.66 billion yuan, maintaining stable profit growth despite overall sector challenges [16][17]

Core Points - The company announced a cash dividend distribution of 0.1 yuan per share (including tax) for the fiscal year 2024, approved at the annual shareholders' meeting on May 27, 2025 [2][4] - The total cash dividend to be distributed amounts to 197,737,144.60 yuan (including tax), based on a total share capital of 1,977,371,446 shares [4] Distribution Details - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the registration date [3] - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited Shanghai Branch to shareholders who have completed designated transactions [5] Taxation Information - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in an actual cash dividend of 0.1 yuan per share [10] - For individual shareholders holding shares for one year or less, the company will not withhold personal income tax at the time of distribution, and the tax will be calculated based on the holding period upon transfer of shares [10] - For Qualified Foreign Institutional Investors (QFII), a 10% corporate income tax will be withheld, resulting in a net cash dividend of 0.09 yuan per share [11]

截至2025年6月13日收盘，天坛生物（600161）报收于19.43元，较上周的20.15元下跌3.57%。本周，天 坛生物6月10日盘中最高价报20.56元。6月13日盘中最低价报19.38元。天坛生物当前最新总市值384.2亿 元，在生物制品板块市值排名5/50，在两市A股市值排名350/5150。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：天坛生物2024年年度权益分派实施，A股每股现金红利0.1元（含税） 公司公告汇总 天坛生物2024年年度权益分派实施公告指出，A股每股现金红利为0.1元（含税）。股权登记日为2025年 6月19日，除权（息）日和现金红利发放日均为2025年6月20日。此次利润分配方案以公司总股本 1977371446股为基数，每股派发现金红利0.1元（含税），共计派发现金红利197737144.60元（含税）。 分配对象为截至股权登记日下午上海证券交易所收市后，在中国结算上海分公司登记在册的本公司全体 股东。对于持有公司无限售条件流通股的自然人股东及证券投资基金，个人持股期限超过1年 ...

Core Viewpoint - The company announced a cash dividend distribution plan, with a cash dividend of 0.1 yuan per share (including tax) for A shares, totaling approximately 197.74 million yuan to be distributed to shareholders [1][2]. Dividend Distribution Plan - The profit distribution plan was approved at the 2024 annual general meeting held on May 27, 2025 [1]. - The total share capital before the distribution is 1,977,371,446 shares, leading to a total cash dividend distribution of 197,737,144.60 yuan (including tax) [1]. Relevant Dates - The key dates for the dividend distribution are as follows: - Equity registration date: June 19, 2025 - Last trading date: June 20, 2025 - Ex-dividend date: June 20, 2025 - Cash dividend payment date: June 20, 2025 [1]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares, the actual cash dividend received will vary based on the holding period: - Holding period within 1 month: 20% tax, resulting in 0.08 yuan per share after tax - Holding period between 1 month and 1 year: 10% tax, resulting in 0.09 yuan per share after tax - Holding period over 1 year: exempt from personal income tax, resulting in 0.1 yuan per share [2]. - For Qualified Foreign Institutional Investors (QFII), a 10% corporate income tax will be withheld, leading to a net cash dividend of 0.09 yuan per share [3][5]. - For other institutional investors and corporate shareholders, the company will not withhold tax, and the actual cash dividend will be 0.1 yuan per share before tax [5]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Board Office at 010-65439720 [5].

每经记者｜郑步春 每经编辑｜彭水萍 继周一及周二来回震荡后，周四A股转为窄幅横盘，消息面暂时平静。截至收盘，上证综指微涨0.01% 至3402.66点；深综指微涨0.15%，创业板综指涨0.43%，科创50指数跌0.3%，北证50指数跌0.25%。全A 总成交额为13036亿元，较周三的12867亿元微有放大。 从行业来看，贵金属、美容护理、珠宝首饰、多元金融、文化传媒、家用轻工、生物制品等板块涨幅居 前，航运港口、酿酒行业、电子化学品等板块跌幅居前。 汇市方面，已横盘数日的美元指数于周三后半盘开始明显走弱，周三美元指数最终跌0.42%，周四亚欧 交易时段再度下跌，至北京时间16时左右暂跌0.3%至98.33点。人民币汇率周三小幅贬值，周四明显升 值，至上述时间暂于7.185上下波动。 美元下跌与新公布物价数据相关，隔夜美国公布的5月CPI同比涨2.4%，低于预期的2.5%；5月CPI环比 涨0.1%，低于预期的0.2%。在数据公布前，市场中曾有个说法，即关税战有可能使5月物价指标大幅超 预期，故事实上弱于预期的CPI数据公布后即对美元构成些压力，因市场认为美联储或有更大理由降 息。 顺便说下，美国总统特朗普 ...

生物制品板块短线拉升，派林生物（000403）涨停，荣昌生物、长春高新（000661）、君实生物、百普 赛斯（301080）、诺诚健华等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

导读：医药，这个曾经被寄予厚望的"黄金赛道"，在过去几年遭遇了最漫长的"寒冬"。但是在医药基金的冬天中，优秀 的医药投资团队并没有"冬眠"。当行业进入反转后，机会一定是留给有准备的人。 2025年，A股市场呈现了比较明显的结构性行情。截至6月9日，沪深300指数下跌了-1.26%，但基金业绩的表现出现了 很大差异，这种差异背后主要来自基金经理的阿尔法能力。 以今年的医药板块为例，不少医药基金表现突出，让大家"误认为"今年是一次医药板块的整体性牛市。但是，根据Wind 的数据统计，医药生物板块今年的涨幅为10.29%，并不突出 （数据来源：Wind；数据截至：2025年6月9日） 。 数据来源：Wind；数据截至：2025年6月9日 政策产业共振， 医药投资窗口全面开启 当下的医药投资领域，正迎来政策东风、产业质变、全球共振与业绩兑现的多重利好叠加期，创新药赛道的投资价值正 以肉眼可见的速度迸发。 从政策维度看，顶层设计正为创新药产业铺设高速跑道。《全链条支持创新药发展实施方案》政策的落地，犹如为行业 注入"强心剂"——发展创新药关系医药产业发展，关系人民健康福祉。要全链条强化政策保障，统筹用好价格管理、医 保 ...

Core Insights - The report highlights the growth in employment and average salaries within listed companies in China, indicating a positive trend in the job market post-pandemic [1][10]. Employment Growth - The total number of employees in listed companies in China exceeded 25 million in 2024, showing a continuous increase since the pandemic [1]. - The average monthly salary for employees in these companies is approximately 10,800 yuan [1]. Industry Employment Distribution - The financial, automotive, construction, real estate, and consumer electronics sectors are the largest employers, accounting for 36.2% of the total employment in listed companies [1]. - State-owned banks employ the most individuals, with 1.655 million employees, representing 6.5% of total employment [1]. - The passenger vehicle sector has seen significant growth, with an employee count of 1.409 million, reflecting a 21.3% increase [1][2]. Sector-Specific Employment Trends - The automotive and consumer electronics industries have contributed significantly to new job creation, with the passenger vehicle sector alone adding 248,000 jobs, which is 38% of the total increase across all industries [2][3]. - Export-related industries have also shown consistent growth, with the export scale surpassing 25 trillion yuan in 2024, marking a 7.1% year-on-year increase [3]. Declining Employment Sectors - The insurance and real estate development sectors have experienced a decline in employee numbers, with retail and real estate being the most affected [4][5]. - The general retail sector's employee count has fallen to below 70% of its 2019 levels [5]. Salary Trends - Industries such as telecommunications services, chemical products, and automotive services have seen significant increases in average monthly salaries, with growth rates of 14.9%, 11.0%, and 9.6% respectively [7]. - Conversely, sectors like tourism retail, photovoltaic equipment, and securities have experienced notable salary declines, with reductions of 16.7%, 12.2%, and 9.6% [8]. Market Demand Indicators - Industries such as engineering machinery, bioproducts, and semiconductors are experiencing strong demand, as indicated by the growth in employee numbers and average salaries [9].

Core Viewpoint - The recent death of a young female tourist in Sanya due to a suspected snake bite has raised concerns about the availability and adequacy of antivenom supply in hospitals, particularly in regions with high incidences of snake bites [1][2][4]. Antivenom Production and Availability - Currently, there is only one company, Sairun Biotech, that produces antivenom in China, with only four types available: for pit vipers, cobras, five-step snakes, and banded krait [6][7]. - In 2024, Sairun Biotech reported a revenue of 158 million yuan from antivenom sales, a slight increase of 1.17% year-on-year, with a production volume of 172,900 vials, up 46.68% from the previous year [7]. Treatment Protocols and Challenges - The treatment of snake bites is highly dependent on the experience of medical professionals, emphasizing the need for timely administration of antivenom based on clinical symptoms rather than waiting for definitive identification of the snake species [3][4]. - The guidelines recommend early and adequate use of antivenom, which is crucial for improving patient outcomes [5][4]. Regional Variations in Antivenom Storage - Hospitals in regions with high snake bite incidents, such as Xiangtan, Guangzhou, and Lishui, maintain stocks of the four types of antivenom based on local snake species prevalence [8][9]. - Some hospitals may not stock antivenom due to high costs, short shelf life, and the financial burden of expired products [10][9]. Public Health Implications - Snake bites are a significant public health issue in China, with an estimated 250,000 to 280,000 cases annually, predominantly affecting individuals over 50 years old [4]. - The lack of awareness and access to proper treatment can lead to severe complications and fatalities, highlighting the need for better public health education and resources [13][12]. Future Developments - There is potential for market growth in antivenom production, as current offerings do not cover all snake species, and additional companies are exploring the development of new antivenoms [13][15]. - Sairun Biotech is currently conducting clinical research on antivenom for viper bites, which could expand treatment options in the future [15][16].